IL148496A0 - Therapeutic quinazoline derivatives - Google Patents
Therapeutic quinazoline derivativesInfo
- Publication number
- IL148496A0 IL148496A0 IL14849600A IL14849600A IL148496A0 IL 148496 A0 IL148496 A0 IL 148496A0 IL 14849600 A IL14849600 A IL 14849600A IL 14849600 A IL14849600 A IL 14849600A IL 148496 A0 IL148496 A0 IL 148496A0
- Authority
- IL
- Israel
- Prior art keywords
- therapeutic
- quinazoline derivatives
- quinazoline
- derivatives
- therapeutic quinazoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9922171.5A GB9922171D0 (en) | 1999-09-21 | 1999-09-21 | Chemical compounds |
PCT/GB2000/003593 WO2001021597A1 (en) | 1999-09-21 | 2000-09-19 | Therapeutic quinazoline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
IL148496A0 true IL148496A0 (en) | 2002-09-12 |
Family
ID=10861217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14849600A IL148496A0 (en) | 1999-09-21 | 2000-09-19 | Therapeutic quinazoline derivatives |
Country Status (24)
Country | Link |
---|---|
US (1) | US7235559B1 (no) |
EP (1) | EP1218355A1 (no) |
JP (1) | JP2003509500A (no) |
KR (1) | KR20020030123A (no) |
CN (1) | CN1391563A (no) |
AR (1) | AR025735A1 (no) |
AU (1) | AU762697B2 (no) |
BG (1) | BG106526A (no) |
BR (1) | BR0014137A (no) |
CA (1) | CA2384296A1 (no) |
CO (1) | CO5200783A1 (no) |
CZ (1) | CZ20021008A3 (no) |
EE (1) | EE200200118A (no) |
GB (1) | GB9922171D0 (no) |
HK (1) | HK1046685A1 (no) |
HU (1) | HUP0300205A3 (no) |
IL (1) | IL148496A0 (no) |
IS (1) | IS6310A (no) |
NO (1) | NO20021400L (no) |
PL (1) | PL354870A1 (no) |
SK (1) | SK3872002A3 (no) |
TR (1) | TR200200717T2 (no) |
WO (1) | WO2001021597A1 (no) |
ZA (1) | ZA200202232B (no) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6919338B2 (en) * | 2000-06-28 | 2005-07-19 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase |
WO2002036587A2 (en) | 2000-11-01 | 2002-05-10 | Cor Therapeutics, Inc. | Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides |
JP2002293773A (ja) * | 2001-03-30 | 2002-10-09 | Sumika Fine Chemicals Co Ltd | キナゾリン誘導体の製造方法 |
EP1408980A4 (en) | 2001-06-21 | 2004-10-20 | Ariad Pharma Inc | NEW QUINAZOLINES AND THEIR USE |
WO2003035602A1 (fr) * | 2001-10-25 | 2003-05-01 | Sankyo Company, Limited | Modulateurs lipidiques |
RU2323215C2 (ru) | 2001-12-24 | 2008-04-27 | Астразенека Аб | Замещенные производные хиназолина как ингибиторы ауроракиназы |
MXPA04006882A (es) | 2002-01-17 | 2004-12-06 | Neurogen Corp | Analogos substituidos de quinazolin-4-ilamina como moduladores de receptores de capsaicina. |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
US7176310B1 (en) | 2002-04-09 | 2007-02-13 | Ucb Sa | Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents |
EP1548008A4 (en) * | 2002-08-23 | 2008-08-06 | Kirin Pharma Kk | COMPOUND HAVING BETA-TRANSFORMING GROWTH FACTOR INHIBITORY ACTIVITY AND DRUG CONTAINING COMPOSITION |
WO2004041829A1 (en) | 2002-11-04 | 2004-05-21 | Astrazeneca Ab | Quinazoline derivatives as src tyrosine kinase inhibitors |
US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
RS20060097A (en) | 2002-12-20 | 2008-11-28 | Pfizer Products Inc., | Pyrimidine derivatives for the treatment of abnormal cell growth |
AU2003292435A1 (en) * | 2002-12-23 | 2004-07-14 | Astrazeneca Ab | 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents |
WO2004058267A1 (en) * | 2002-12-23 | 2004-07-15 | Ariad Pharmaceuticals, Inc. | Heterocycles and uses thereof |
WO2004056801A1 (en) * | 2002-12-23 | 2004-07-08 | Astrazeneca Ab | Quinazoline derivatives |
ATE412657T1 (de) * | 2002-12-24 | 2008-11-15 | Astrazeneca Ab | Therapeutische quinazolin-derivate |
MXPA05006920A (es) | 2002-12-24 | 2006-02-10 | Astrazeneca Ab | Compuestos de quinazolina. |
DK1847539T3 (da) | 2002-12-24 | 2009-11-09 | Astrazeneca Ab | Quinazolin-derivater |
CA2522079A1 (en) * | 2003-04-16 | 2004-11-04 | Astrazeneca Ab | Quinazoline derivatives for treatment of cancer |
ES2308182T3 (es) * | 2003-06-02 | 2008-12-01 | Astrazeneca Ab | Derivadosde (3-((quinazolin-4-il)amino)-1h-pirazol-1-il)acetamida y compuestos relacionados como inhibidores de quinasas aurora para el tratamiento de enfermedades proliferativas tales como el cancer. |
WO2004108710A1 (en) * | 2003-06-05 | 2004-12-16 | Astrazeneca Ab | 4-pyrimidinyl quinazoline derivatives for use in the treatment of tumours |
WO2004108707A1 (en) * | 2003-06-05 | 2004-12-16 | Astrazeneca Ab | Pyridazinil quinazoline derivatives for use in the treatment of tumours |
WO2004108711A1 (en) * | 2003-06-05 | 2004-12-16 | Astrazeneca Ab | Pyrazinil quinazoline derivatives for use in the treatment of tumours |
TW200505452A (en) * | 2003-06-17 | 2005-02-16 | Astrazeneca Ab | Chemical compounds |
US7329664B2 (en) | 2003-07-16 | 2008-02-12 | Neurogen Corporation | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues |
US7452895B2 (en) * | 2003-08-14 | 2008-11-18 | Array Biopharma Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
EP2612853A1 (en) | 2003-09-26 | 2013-07-10 | Exelixis Inc. | c-Met modulators and methods of use |
US7326712B2 (en) * | 2003-10-14 | 2008-02-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Substituted tricyclic compounds as protein kinase inhibitors |
US20090099165A1 (en) | 2003-10-14 | 2009-04-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
AU2004285052A1 (en) * | 2003-10-31 | 2005-05-12 | Neurogen Corporation | 4-amino (AZA) quinoline derivatives as capsaicin receptor agonists |
EP1713781B1 (en) | 2004-02-03 | 2008-11-05 | AstraZeneca AB | Quinazoline derivatives |
BRPI0510963A (pt) | 2004-05-14 | 2007-11-20 | Pfizer Prod Inc | derivados pirimidina para o tratamento do crescimento anormal de células |
MXPA06011658A (es) | 2004-05-14 | 2006-12-14 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento del crecimiento celular anormal. |
BRPI0510980A (pt) | 2004-05-14 | 2007-11-27 | Pfizer Prod Inc | derivados de pirimidina para o tratamento do crescimento anormal de células |
US7285569B2 (en) | 2004-09-24 | 2007-10-23 | Hoff Hoffmann-La Roche Inc. | Tricycles, their manufacture and use as pharmaceutical agents |
AR050948A1 (es) | 2004-09-24 | 2006-12-06 | Hoffmann La Roche | Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer. |
AU2005293336B2 (en) | 2004-10-12 | 2009-05-28 | Astrazeneca Ab | Quinazoline derivatives |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
WO2006104971A1 (en) * | 2005-03-28 | 2006-10-05 | Bristol-Myers Squibb Company | Atp competitive kinase inhibitors |
WO2006108489A1 (en) | 2005-04-14 | 2006-10-19 | F. Hoffmann-La Roche Ag | Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents |
GB0509227D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
JP2009528336A (ja) * | 2006-03-02 | 2009-08-06 | アストラゼネカ アクチボラグ | キノリン誘導体 |
SG175609A1 (en) | 2006-10-09 | 2011-11-28 | Takeda Pharmaceutical | Kinase inhibitors |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
MX2009007610A (es) | 2007-02-06 | 2009-07-24 | Boehringer Ingelheim Int | Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion. |
US7776857B2 (en) | 2007-04-05 | 2010-08-17 | Amgen Inc. | Aurora kinase modulators and method of use |
CN101215274B (zh) * | 2007-12-27 | 2011-05-04 | 上海北卡医药技术有限公司 | N取代吗啉类有机化合物的制备工艺 |
WO2009098061A1 (de) | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
WO2009117157A1 (en) | 2008-03-20 | 2009-09-24 | Amgen Inc. | Aurora kinase modulators and method of use |
NZ589883A (en) | 2008-05-13 | 2012-06-29 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline |
JP5539351B2 (ja) | 2008-08-08 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法 |
US9126935B2 (en) | 2008-08-14 | 2015-09-08 | Amgen Inc. | Aurora kinase modulators and methods of use |
MX2011004018A (es) * | 2008-10-14 | 2011-06-24 | Ning Xi | Compuestos y metodos de uso. |
EP2241565A1 (en) | 2009-01-15 | 2010-10-20 | Universität Leipzig | Aurora kinase inhibitors compounds |
TWI447108B (zh) | 2009-01-16 | 2014-08-01 | Exelixis Inc | N-(4-{〔6,7雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽及其結晶型 |
KR20110133048A (ko) * | 2009-03-21 | 2011-12-09 | 닝 시 | 아미노 에스테르 유도체, 그의 염 및 이용 방법 |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
GB201021103D0 (en) * | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | New compounds for the treatment of neurodegenerative diseases |
CN103304489B (zh) * | 2012-03-16 | 2015-03-11 | 中国农业科学院兰州畜牧与兽药研究所 | 嘧啶苯甲酰胺类化合物及其制备和应用 |
AP2016009088A0 (en) | 2013-09-16 | 2016-03-31 | Astrazeneca Ab | Therapeutic polymeric nanoparticles and methods of making and using same |
SI3089971T1 (sl) | 2014-01-01 | 2020-11-30 | Medivation Technologies Llc | Spojine in postopki za uporabo |
HUE057041T2 (hu) | 2015-07-06 | 2022-04-28 | Alkermes Inc | Hiszton deacetiláz hetero-halogén gátlói |
WO2017007755A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
EP3184507A1 (en) * | 2015-12-22 | 2017-06-28 | Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO | Preparation of phenyl compounds |
MD3570834T2 (ro) | 2017-01-11 | 2022-04-30 | Alkermes Inc | Inhibitori biciclici ai histon deacetilazei |
WO2019032528A1 (en) | 2017-08-07 | 2019-02-14 | Rodin Therapeutics, Inc | BICYCLIC HISTONE DEACETYLASE INHIBITORS |
CN110746398A (zh) * | 2019-10-18 | 2020-02-04 | 刘沛友 | 4-杂环取代喹唑啉类衍生物及其制备方法和用途 |
CN114436975B (zh) * | 2022-01-26 | 2023-10-31 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 2-三氟甲基-4-氨基喹唑啉类化合物及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
GB9800575D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
EP1162974A1 (en) * | 1999-03-19 | 2001-12-19 | Parker Hughes Institute | Quinazoline formulations and therapeutic use thereof |
US6258820B1 (en) * | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
-
1999
- 1999-09-21 GB GBGB9922171.5A patent/GB9922171D0/en not_active Ceased
-
2000
- 2000-09-19 KR KR1020027003680A patent/KR20020030123A/ko not_active Application Discontinuation
- 2000-09-19 WO PCT/GB2000/003593 patent/WO2001021597A1/en not_active Application Discontinuation
- 2000-09-19 US US10/088,856 patent/US7235559B1/en not_active Expired - Fee Related
- 2000-09-19 JP JP2001524976A patent/JP2003509500A/ja active Pending
- 2000-09-19 CN CN00816012A patent/CN1391563A/zh active Pending
- 2000-09-19 TR TR2002/00717T patent/TR200200717T2/xx unknown
- 2000-09-19 PL PL00354870A patent/PL354870A1/xx not_active Application Discontinuation
- 2000-09-19 SK SK387-2002A patent/SK3872002A3/sk unknown
- 2000-09-19 CZ CZ20021008A patent/CZ20021008A3/cs unknown
- 2000-09-19 HU HU0300205A patent/HUP0300205A3/hu unknown
- 2000-09-19 EP EP00960850A patent/EP1218355A1/en not_active Withdrawn
- 2000-09-19 EE EEP200200118A patent/EE200200118A/xx unknown
- 2000-09-19 BR BR0014137-2A patent/BR0014137A/pt not_active IP Right Cessation
- 2000-09-19 AU AU73019/00A patent/AU762697B2/en not_active Ceased
- 2000-09-19 IL IL14849600A patent/IL148496A0/xx unknown
- 2000-09-19 CA CA002384296A patent/CA2384296A1/en not_active Abandoned
- 2000-09-21 AR ARP000104956A patent/AR025735A1/es unknown
- 2000-09-21 CO CO00071838A patent/CO5200783A1/es not_active Application Discontinuation
-
2002
- 2002-03-18 BG BG106526A patent/BG106526A/xx unknown
- 2002-03-19 IS IS6310A patent/IS6310A/is unknown
- 2002-03-19 ZA ZA200202232A patent/ZA200202232B/en unknown
- 2002-03-20 NO NO20021400A patent/NO20021400L/no unknown
- 2002-11-19 HK HK02108371.0A patent/HK1046685A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
NO20021400L (no) | 2002-05-06 |
IS6310A (is) | 2002-03-19 |
US7235559B1 (en) | 2007-06-26 |
HUP0300205A2 (en) | 2003-05-28 |
GB9922171D0 (en) | 1999-11-17 |
JP2003509500A (ja) | 2003-03-11 |
CZ20021008A3 (cs) | 2002-06-12 |
HUP0300205A3 (en) | 2003-08-28 |
SK3872002A3 (en) | 2002-12-03 |
BG106526A (en) | 2002-10-31 |
KR20020030123A (ko) | 2002-04-22 |
AR025735A1 (es) | 2002-12-11 |
HK1046685A1 (zh) | 2003-01-24 |
CN1391563A (zh) | 2003-01-15 |
PL354870A1 (en) | 2004-03-08 |
NO20021400D0 (no) | 2002-03-20 |
CA2384296A1 (en) | 2001-03-29 |
BR0014137A (pt) | 2002-05-21 |
ZA200202232B (en) | 2003-08-27 |
WO2001021597A1 (en) | 2001-03-29 |
CO5200783A1 (es) | 2002-09-27 |
TR200200717T2 (tr) | 2002-06-21 |
EP1218355A1 (en) | 2002-07-03 |
EE200200118A (et) | 2003-04-15 |
AU762697B2 (en) | 2003-07-03 |
AU7301900A (en) | 2001-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL148496A0 (en) | Therapeutic quinazoline derivatives | |
HK1200316A1 (en) | Therapeutic microfoams | |
HK1092804A1 (en) | New quinazoline derivatives | |
GB9911863D0 (en) | Therapeutic agents | |
GB9905010D0 (en) | Therapeutic agents | |
GB9904786D0 (en) | Therapeutic agents | |
GB9930570D0 (en) | Therapy | |
EG23858A (en) | Drug combination | |
GB9911881D0 (en) | Therapeutic agents | |
GB9907243D0 (en) | Therapy | |
GB9911802D0 (en) | Therapeutic combination | |
GB9903476D0 (en) | Therapeutic agents | |
GB9911803D0 (en) | Therapeutic combination | |
GB9911804D0 (en) | Therapeutic combination | |
GB9900222D0 (en) | Therapeutic compounds | |
GB9914744D0 (en) | Therapeutic agents | |
GB9903119D0 (en) | Therapeutic agents | |
GB9914745D0 (en) | Therapeutic agents | |
GB9914742D0 (en) | Therapeutic agents | |
GB9902881D0 (en) | Therapeutic agents | |
GB9914743D0 (en) | Therapeutic agents | |
GB9911238D0 (en) | Therapeutic use | |
GB9915616D0 (en) | Therapeutic agents | |
GB9913350D0 (en) | Therapeutic use | |
GB9912184D0 (en) | Therapeutic use |